Abstract 4031: In vivo studies demonstrate differences in target inhibition and anticancer efficacy between NXP900 and dasatinib in ovarian clear cell carcinoma model

Saúl Navarro-Marchal, Carolin Temps, Iñigo Lanzagorta-Calvillo, John C. Dawson, Enrique Poradosu, Neil O. Carragher, Valerie G. Brunton, Asier Unciti-Broceta

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)4031-4031
JournalCancer Research
Issue number7_Supplement
Publication statusPublished - 1 Apr 2023

Cite this